Autoinhibition of Bcr-Abl through its SH3 domain

Molecular Cell

Volumn 12, Issue 1, 2003, Pages 27-37

  Smith, Kristen M ^a   Yacobi, Rinat ^a   Van Etten, Richard A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PHOSPHOTRANSFERASE; PROLINE DERIVATIVE; PROTEIN; PROTEIN SH3; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENE MUTATION; LEUKEMOGENESIS; MOUSE; NONHUMAN; OLIGOMERIZATION; PHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION;

ANIMALIA;

EID: 0042170248     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(03)00274-0     Document Type: Article

References (39)

1. Azam M., Latek R.R., Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112:2003;831-843.
2. Barila D., Superti-Furga G. An intramolecular SH3domain interaction regulates c-Abl activity. Nat. Genet. 18:1998;280-282.
3. Brasher B.B., Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 275:2000;35631-35637.
4. Brasher B.B., Roumiantsev S., Van Etten R.A. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene. 20:2001;7744-7752.
5. Dorey K., Engen J.R., Kretzschmar J., Wilm M., Neubauer G., Schindler T., Superti-Furga G. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene. 20:2001;8075-8084.
6. Echarri A., Pendergast A.M. Activated c-Abl is degraded by the ubiquitin-proteasome pathway. Curr. Biol. 11:2001;1759-1765.
7. Franz W.M., Berger P., Wang J.Y.J. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 8:1989;137-147.
8. Hantschel O., Nagar B., Guettler S., Kretzschmar J., Dorey K., Kuriyan J., Superti-Furga G. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 112:2003;845-857.
9. He Y., Wertheim J.A., Xu L., Miller J.P., Karnell F.G., Choi J.K., Ren R., Pear W.S. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood. 99:2002;2957-2968.
10. Kantarjian H., Sawyers C.L., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U.et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346:2002;645-652.
11. Konopka J.B., Witte O.N. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol. Cell. Biol. 5:1985;3116-3123.
12. Li S., Ilaria R.L., Million R.P., Daley G.Q., Van Etten R.A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189:1999;1399-1412.
13. Luo Z., Matthews A.M., Weiss S.R. Amino acid substitutions within the leucine zipper domain of the murine coronavirus spike protein cause defects in oligomerization and the ability to induce cell-to-cell fusion. J. Virol. 73:1999;8152-8159.
14. Maru Y., Witte O.N., Shibuya M. Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence. FEBS Lett. 379:1996;244-246.
15. McLaughlin J., Chianese E., Witte O.N. In vitro transformation of immature hematopoietic cells by the P210 bcr/abl oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA. 84:1987;6558-6562.
16. McWhirter J.R., Wang J.Y.J. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of the Philadelphia chromosome-positive leukemias. EMBO J. 12:1993;1533-1546.
17. McWhirter J.R., Wang J.Y.J. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene. 15:1997;1625-1634.
18. McWhirter J.R., Galasso D.L., Wang J.Y.J. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13:1993;7587-7595.
19. Million R.P., Van Etten R.A. The Grb2 binding site is required for induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood. 96:2000;664-670.
20. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., Clarkson B., Superti-Furga G., Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 112:2003;859-871.
21. Pendergast A.M. The Abl family kinases. mechanisms of regulation and signaling Adv. Cancer Res. 85:2002;51-100.
22. Pendergast A.M., Muller A.J., Havlik M.H., Clark R., McCormick F., Witte O.N. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc. Natl. Acad. Sci. USA. 88:1991;5927-5931. a.
23. Pendergast A.M., Muller A.J., Havlik M.H., Maru Y., Witte O.N. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 66:1991;161-171. b.
24. Pendergast A.M., Gishizky M.L., Havlik M.H., Witte O.N. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol. Cell. Biol. 13:1993;1728-1736.
25. Plattner R., Kadlec L., DeMali K.A., Kazlauskas A., Pendergast A.M. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 13:1999;2400-2411.
26. Plattner R., Irvin B.J., Guo S., Blackburn K., Kazlauskas A., Abraham R.T., York Y.D., Pendergast A.M. A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1. Nat. Cell Biol. 5:2003;309-319.
27. Pluk H., Dorey K., Superti-Furga G. Autoinhibition of c-Abl. Cell. 108:2002;247-260.
28. Roumiantsev S., de Aos I., Varticovski L., Ilaria R.L., Van Etten R.A. The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood. 97:2001;4-13.
29. Roumiantsev S., Shah N.P., Gorre M.E., Nicoll J., Brasher B.B., Sawyers C.L., Van Etten R.A. Clinical resistance to the kinase inhibitor STI-571 in CML by mutation of Tyr253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA. 99:2002;10700-10705.
30. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science. 289:2000;1938-1942.
31. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 13:2000;211-225.
32. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:2002;117-125.
33. Sicheri F., Moarefi I., Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature. 385:1997;602-609.
34. Smith K.M., Van Etten R.A. Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization. J. Biol. Chem. 276:2001;24372-24379.
35. + leukemia in mice. Oncogene. 21:2002;8643-8651.
36. Van Etten R.A., Debnath J., Zhou H., Casasnovas J.M. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro. Oncogene. 10:1995;1977-1988.
37. Wen S.-T., Van Etten R.A. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 11:1997;2456-2467.
38. 2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol. Cell. Biol. 21:2001;840-853.
39. Zhao X., Ghaffari S., Lodish H., Malashkevich V.N., Kim P.S. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat. Struct. Biol. 9:2002;117-120.